The VICTORY Study
Research type
Research Study
Full title
A single visit, cross-sectional, observational study of EBC H2O2 levels and other exhaled breath condensate parameters, as measured by ‘Inflammacheck™’, in people with a variety of respiratory conditions and volunteers with no known lung disease. The VICTORY Study
IRAS ID
271130
Contact name
Anoop Chauhan
Contact email
Sponsor organisation
Portsmouth Hospitals NHS Trust
Duration of Study in the UK
1 years, 3 months, 21 days
Research summary
Lung disease affects approximately 1 in 5 people in the UK, leading to over 700,000 hospital admissions per year. It is estimated that each week 10,000 people are given a new diagnosis of lung disease but there are thousands more living with symptoms without a diagnosis.
People with lung conditions can suffer significantly with their symptoms and often require multiple trips to their GP or secondary care before a diagnosis is made. It can be difficult to diagnose lung disease and to differentiate between different lung conditions, so many people may be misdiagnosed or incorrectly not given a diagnosis. The tests currently used to diagnose lung diseases can be difficult or uncomfortable to do, especially if the person is experiencing lots of symptoms, and therefore can give poor or unreliable results.
A new quick and easy to perform test is needed that can differentiate between various lung conditions and people with no lung disease, that can be performed in primary and secondary care with immediate results.
‘Inflammacheck™’ is a test which can measure different chemicals and lung function properties from an exhaled breath. These chemicals have been linked by previous studies to levels of inflammation in the lung, and the levels of these chemicals are very different in people with asthma and COPD, and healthy individuals. Other lung function properties such as temperature, humidity and carbon dioxide have never been tested together in one device and from a single reading. Previous studies have allowed us to improve the accuracy and use of the device, and we now wish to test all these together from people with and without lung disease. Our earlier tests have already shown significant differences in a chemical hydrogen peroxide between healthy individuals and those with asthma, COPD, lung fibrosis and lung cancer.
REC name
South Central - Berkshire Research Ethics Committee
REC reference
19/SC/0462
Date of REC Opinion
4 Sep 2019
REC opinion
Favourable Opinion